Calidi Biotherapeutics appoints Eric Poma as CEO to lead next phase of cancer virotherapy development
- Apr 23, 2025
- 1 min read
San Diego, CA, April 23, 2025 (Globe Newswire) -- Eric Poma, Ph.D., has been appointed CEO of Calidi Biotherapeutics, succeeding Allan Camaisa, who remains on the Board. The transition supports Calidi’s next clinical milestone: a dose-escalation trial of its virotherapy candidate CLD-201. The company highlights Poma’s oncology expertise as vital to advancing its platform for hard-to-treat cancers.
Read full article here.
Comments